Sarfaraz K. Niazi, PhD, outlines how President Joe Biden's new budget for 2025 could impact biosimilars, including provisions to clear up confusion surrounding interchangeable products.
The FY 2025 US budget announced on March 11 is one of the rare admissions of why the cost of pharmaceuticals per capita is the highest globally. The FY 2025 budget includes several legislative proposals supporting the FDA's efforts to protect American consumers and patients. Of the dozens of proposals, the significant ones for the generic industry are:
The extension of the ingredient listing requirement of parenteral products to chemical drugs.
Amending certain exclusivity provisions for drugs to encourage meaningful innovation and timely competition. FDA is seeking to encourage competition for new drugs by proposing to amend the Hatch-Waxman 3-year exclusivity provisions to ensure that this exclusivity is limited to situations where the new drug applicant is seeking such exclusivity and where the data supporting the exclusivity demonstrates the hypothesized effect of the drug and to prevent information on new safety risks from blocking competition. This approach would continue to reward innovation while allowing earlier access to generic drugs in certain situations.
However, the most relevant suggestion is to eliminate the statutory distinction between the approval standard for biosimilar and interchangeable biosimilar products and deem approved biosimilars interchangeable. The statutory distinction between biosimilars and interchangeable biosimilars has led to confusion and misunderstanding among patients and health care providers about the safety and effectiveness of biosimilars and whether interchangeable biosimilars are safer or more effective than other biosimilars. This proposal would make the US biosimilar program more consistent with current scientific understanding and the approach adopted by other major regulatory jurisdictions, such as the European Union, where biosimilars are interchangeable with their respective reference products upon approval. Further, this proposal is expected to increase the uptake of biosimilars, with potential downstream effects of increasing competition, access, and affordability.
However, the FDA is taking a different approach when FDA Commissioner Robert Califf, MD, said approval from Congress is still the best pathway to making the change than just declaring biosimilars interchangeable; the FDA is seeking to amend section 351 of the Public Health Service Act to no longer include a separate statutory standard for a determination of interchangeability and to deem all approved biosimilars to be interchangeable with their respective reference products. This is a wrong decision by the FDA, since such legislative changes are difficult to achieve, and often get tossed out due to many conflicts of interest. Notably, the US Senate has a bill pending to do just that, and I have provided support through my publications and meetings with senators, but it is going nowhere. Before the release of the FY 2025 budget, I was consulted by the White House, and I was able to present a solid scientific argument, avoiding cost savings as the primary reason. I am glad to see this provision in the budget, but I am not sure if the FDA fully supports it and instead waits for the amendment to 351(k), and indeed, the big pharma has already launched a campaign to prevent this from happening.
Eye on Pharma: EC Approved Ustekinumab; Zymfentra Expansion; Biosimilar Policy Briefing
September 26th 2024The European Commission (EC) approved Celltrion's ustekinumab biosimilar for chronic inflammatory diseases, Celltrion expanded access to Zymfentra (subcutaneous infliximab-dyyb) through partnerships with Cigna and Express Scripts, and the Association for Accessible Medicines held a policy briefing addressing barriers to biosimilar adoption.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
BioRationality—The Missing Rationality in Biosimilar Discussions and the Path Forward
September 23rd 2024The article by Sarfaraz K. Niazi, PhD, critiques the irrationality surrounding biosimilars, suggesting that regulatory changes and cost reductions in manufacturing could make biosimilars as affordable as generic drugs.